Shortened leukocyte telomere length in type 2 diabetes mellitus: genetic polymorphisms in mitochondrial uncoupling proteins and telomeric pathways by Yuling Zhou et al.
Zhou et al. Clin Trans Med  (2016) 5:8 
DOI 10.1186/s40169-016-0089-2
REVIEW
Shortened leukocyte telomere 
length in type 2 diabetes mellitus: genetic 
polymorphisms in mitochondrial uncoupling 
proteins and telomeric pathways
Yuling Zhou1, Zhixin Ning1, Yvonne Lee1, Brett D. Hambly2 and Craig S. McLachlan1*
Abstract 
Current debate in type 2 diabetes (T2DM) has focused on shortened leukocyte telomere length (LTL) as the result of a 
number of possible causes, including polymorphisms in mitochondrial uncoupling proteins (UCPs) leading to oxida-
tive stress, telomere regulatory pathway gene polymorphisms, or as a direct result of associated cardiovascular com-
plications inducing tissue organ inflammation and oxidative stress. There is evidence that a heritable shorter telomere 
trait is a risk factor for development of T2DM. This review discusses the contribution and balance of genetic regulation 
of UCPs and telomere pathways in the context of T2DM. We discuss genotypes that are well known to influence the 
shortening of LTL, in particular OBFC1 and telomerase genotypes such as TERC. Interestingly, the interaction between 
short telomeres and T2DM risk appears to involve mitochondrial dysfunction as an intermediate process. A hypothesis 
is presented that genetic heterogeneity within UCPs may directly affect oxidative stress that feeds back to influence 
the fine balance of telomere regulation, cell cycle regulation and diabetes risk and/or metabolic disease progression.
Keywords: Telomere length, Type 2 diabetes, Genetics, Uncoupling protein polymorphisms, Telomere-associated 
pathway genes
© 2016 Zhou et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Telomere length varies from 4–20 kb in humans and tel-
omere shortening is thought to be key mechanistic event 
in cellular aging [1–3]. Shorter telomeres have been 
described as a risk factor for many age related chronic 
conditions [4], including T2DM [5–7]. A current debate 
concerns whether shorter telomeres are a heritable trait 
[8], or a consequence of an associated disease process 
[9, 10] or, in fact due to an age related dysfunction in tel-
omere regulation [11, 12]. Changes in telomere length 
associated with type 2 diabetes (T2DM) and interactions 
between mitochondrial function and telomeres represent 
possible translational targets to treat T2DM by restoring 
telomere length [13–16].
Leukocyte telomere length (LTL) is associated 
with metabolic disease and cardiovascular risk 
factors
There is certainly a growing trend to report telomere 
length in population studies that encompass traditional 
metabolic and cardiovascular risk factors. The large 
community population Framingham heart study has 
demonstrated that cardiovascular risk factors such as 
hypertension and/or insulin resistance are associated 
with shorter human LTLs [17]. Shortened LTLs have 
been observed in patients with metabolic syndrome with 
impaired glycaemic control and increased waist-to-hip 
ratio [18]. Impaired glycaemic control in both clinical and 
translational studies, have been associated with increased 
cellular oxidative stress [19].
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Oxidative stress and LTL in metabolic disease
Diabetes complicated by cardiovascular disease is asso-
ciated with increased mortality and higher levels of oxi-
dative stress and inflammation, which may accelerate 
telomere shortening and associated premature cell senes-
cence [20–22]. Importantly, mitochondrial oxidative 
stress appears to be required to maintain cellular senes-
cence [23]. Additionally, in cancer biology short telomere 
dysfunction has been associated with a tissue decrease 
in mitochondrial DNA copy number and, importantly, 
a decrease in mitochondrial bio-energetic function [24], 
emphasizing a close inter-relationship between oxida-
tive stress, mitochondrial bio-energetic coupling and 
telomere length [25–27]. On the other hand, such asso-
ciations have not been well explored in diabetes. These 
biological factors influencing regulatory telomere path-
ways would be amenable to genetic analysis, particularly 
in populations at risk, such as those that have developed 
T2DM, with and without cardiovascular risk factors.
Do short telomeres cause and/or influence 
progress of T2DM metabolic syndrome?
It is generally accepted that shortened telomeres may 
independently contribute to clinical metabolic syndrome 
progression via directly affecting cellular metabolic rate 
and influencing neighboring cell function [28–30]. For 
example, short telomeres may affect pancreatic β-cell 
metabolism directly [7]. In T2DM, studies have demon-
strated a reduction in both global β-cell signaling and 
production of insulin in the setting of pancreatic cell 
senescence [7]. However, the relationship between LTL 
and obesity [31] and diabetes [32] has been questioned. 
The severity of disease complications may also interact 
with telomere length regulation. For example, in T2DM 
with complications such as a previous myocardial infarc-
tion (MI), telomere length is shorter, compared to the 
presence of T2DM without MI per se [18].
Is the interaction between telomere length 
and T2DM influenced by genetic variation?
Several studies have reported positive associations 
between LTL and T2DM. LTL has been shown to be 
shorter in patients with T2DM and also correlates with 
time of onset and duration of disease [19, 33, 34]. How-
ever, a Chinese population-based study found no rela-
tionship between LTL and either the time of onset or the 
duration of T2DM [35]. Mechanisms other than diabetes 
may be responsible for shorter telomeres in a Chinese 
population. Genetic regulation of telomeres could poten-
tially explain telomere shortening and an increased risk 
for T2DM. Current conceptual thinking is that shorter 
telomeres may predispose to, or accelerate, biological 
aging-related disease by underpinning a bidirectional 
cause-and-effect relationship between disease and tel-
omere length [36]. Possible mechanisms that could result 
in bidirectional changes in both metabolic disease pro-
gression and telomere shortening would be functional 
expression or activity changes in telomere length-related 
genes and pathways and alterations in cellular oxidative 
stress.
Uncoupling protein association
The three common isotypes of UCP are UCP1, mainly 
expressed in brown adipose tissue, UCP2, expressed 
widely in most cells and UCP3, expressed mainly in stri-
ated muscle [37]. UCP2 has been implicated in diabetes 
risk and interactions with telomere-pathways [13, 38].
UCPs are located in the inner mitochondrial mem-
brane and mediate proton leakage, to regulate the pro-
duction of ATP and reduce oxidative stress [37, 39]. The 
high degree of homology at the nucleotide level and the 
conservation of the exon/intron boundaries among the 
key UCP genes (UCP1, UCP2, UCP3) suggests they may 
have evolved from a common ancestor or are the result 
of gene duplication events [40]. Peroxisome prolifer-
ator-activated receptors (PPARs) are ligand-activated 
transcription factors involved in the regulation of glu-
cose/lipid metabolism [41] and are pivotal in the con-
trol of transcription of the UCP family of genes [42, 43] 
Interestingly, pre-clinical studies in Otsuka Long-Evans 
Tokushima fatty (OLETF) rats, that develop T2DM, have 
shown that PPAR-γ is also effective at elevating telomer-
ase activity and telomere-associated proteins [41], ame-
liorating the effects of T2DM on telomere shortening.
Two studies have explored the association between 
the UCP2 gene variant −866G  <  A (rs659366), T2DM 
and telomere length [13, 38]. One study covered a range 
of ethnic backgrounds [13] (Caucasian, South Asian and 
Afro-Caribbean) while the other focused on a Han Chi-
nese population [38]. LTL and the −866G < A UCP2 var-
iant were found to be independent risk factors for T2DM 
[38]. The −866G < A UCP2 variant was also particularly 
related to shorter LTL in patients [13]. These studies 
were some of the first to suggest a possible association 
between the efficiency of mitochondrial UCP regulation 
of reactive oxygen species [44, 45] and shorter telomere 
length in T2DM.
Telomerase and shelterin association
Eukaryotic chromosome stability requires telomere 
maintenance by the RNA-protein telomerase complex, 
which is responsible for reverse transcriptase activity 
for the maintenance of telomere ends, by adding DNA 
sequence repeats [46]. The telomerase holoenzyme 
is composed of both protein and RNA, i.e. telomeric 
reverse transcriptase (TERT), telomeric RNA component 
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(TERC) and other factors, e.g. telomerase protein com-
ponent 1 (TEP1). The function of telomerase relies on 
proper expression, maturation, trafficking and assembly 
of these components [47]. TERT is the catalytic subunit 
of the enzyme telomerase that catalyses the addition of 
multiple 6 bp (TTAGGG) telomere repeats, using TERC 
as a template [48]. TEP1 is a component that facilitates 
telomerase activity.
Moreover, the shelterin complex is recognized as being 
important for the protection of telomeres and for the 
regulation of telomerase activity [49]. Shelterin is com-
prised of six important components: telomere repeat fac-
tor 1 and 2 (TRF1 and TRF2), protection of telomere 1 
(POT1), repressor/activator protein 1 (RAP1), TRF1- and 
TRF2- interacting nuclear protein 2 (TIN2), and tripep-
tidyl-peptidase 1 (TPP1) [50]. The TEL-patch of amino 
acids, on the oligonucleotide/oligosaccharide-binding 
folds of the shelterin component TPP1 is essential to 
recruit telomerase to telomeres [50]. While important, 
there is a paucity of basic biological understanding of 
how the shelterin complex components may interact with 
mitochondrial function and induce insulin resistance [51, 
52], although TIN2 has been shown to be post-transla-
tionally processed in mitochondria and regulates mito-
chondrial oxidative phosphorylation [53].
Zee and associates explored 11 telomere pathway genes 
and their relationship to development of T2DM in a lon-
gitudinal cohort of 22,715 healthy middle-aged Cauca-
sian females, free of diabetes or cardiovascular disease 
at baseline [54]. Gene pathways explored in this cohort 
were telomere maintenance genes, all selected on the 
basis of having had a prior association with LTL. During 
a follow-up period of 13  years, 1445 participants devel-
oped T2DM. Results showed that, using haplotype-block 
analysis, there is an association between several pre-
specified haplotypes of TRF1 and TEP1 with T2DM risk. 
When SNPs were considered individually, SNPs (four 
each from TRF1 and TEP1 and one each from TPP1 and 
TRF2) had differential association with T2DM risk. Only 
one SNP–TRF2 rs4783704, remained significant after 
correction for repeated measures. Absolute changes in 
LTL were unfortunately not determined in this study.
Telomerase specifically recognizes and elongates the 
ends of telomeres using the RNA molecule template, 
TERC [55]. TERC is known to be essential for telomere 
homeostasis [48]. Clinical and epidemiological studies 
have revealed that mutations in TERC lead to premature 
telomere shortening and limited TERC activity result in 
accelerated shortening of telomere [56, 57]. Shen and 
associates have explored telomere pathway genes in 
relation to T2DM, in particular two SNPs, rs12696304 
and rs16847897, located near TERC at 3q26 [58]. These 
SNPs were examined in 4016 Shanghai Han Chinese 
participants; 1936 T2DM patients and 2080 healthy 
controls. Both of these major alleles in regression mod-
els were associated with between 3  years (rs12696304) 
and 4  years (rs16847897) of advanced age-related tel-
omere attrition adjusted for diabetes status [58]. In 
summary, these two TERC-related SNPs correlate with 
LTL of both T2DM patients and controls. Moreover, 
data from functional studies, where TERC is knocked 
down or overexpressed using exogenous mutated 
TERC, suggest non-telomere maintenance functions 
for TERC, such as cell cycle control and p53-dependant 
pathway activation [59, 60]. p53 pathways are of inter-
est as they provide a mechanism linking mitochondrial 
damage, ROS production and DNA damage responses, 
and related cellular growth arrest phenotypes during 
cellular senescence [61–63]. Thus, it is not surprising to 
find that a TERC SNP related to both increased cardio-
vascular disease and also T2DM is characterized by cel-
lular senescence.
Genome‑wide association studies’ findings
General population studies have identified several 
genes through genome-wide association studies as a 
locus for cross-sectional individual variation in LTL 
[64, 65]. A novel relative telomere length locus at chro-
mosome 16q21, an intronic variant (rs74019828) in the 
CSNK2A2 (Casein Kinase 2, Alpha Prime Polypeptide) 
gene, was found in South Asians [65]. Phosphorylation 
by CSNK2A2 plays an important role for regulation of 
telomere length homoeostasis [63]. Oligonucleotide/
oligosaccharide-binding folds containing 1 (OBFC1) is 
involved in the initiation of DNA replication and also 
functions in a telomere-associated complex [66]. Sev-
eral GWAS studies have associated OBFC1 with LTL [64, 
67]. In the latter population study, an OBFC1 genotype 
(rs4387287) was found to be associated with both T2DM 
and LTL, where the mean difference in LTL across the 
homozygous genotypes approximates 400 bp in men and 
180 bp in women [64]. The OBFC1 genotype (rs4387287) 
is associated with a defined rate of LTL shortening in the 
general population, circa 20–30  bp/year [68]. OBFC1 is 
of particular relevance since although it is unrelated to 
oxidative stress or mitochondrial function, it is directly 
engaged in telomere biology [64, 69], suggesting that 
OBFC1 is able to regulate telomere length and/or func-
tion [64].
The relevance of OBFC1 is supported by the find-
ing of Maubaret et  al. [70], where an OBFC1 haplotype 
(rs10786775G and rs11591710C) was associated with 
lower risk of coronary heart disease. They also found 
a TERC haplotype (rs12696304G, rs10936601T and 
rs16847897C) was associated with both a lower risk of 
coronary heart disease and T2DM.
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Another independent study also provides positive evi-
dence for the association between OBFC1 and LTL. You 
et  al. examined rs4387287 on the OBFC1 gene, which 
is associated with LTL, and its association with T2DM 
development. In addition, another nine genes, including 
TERT, TERC, TEP1, TRF1, TRF2, POT1, and TPP1 were 
exmined [71]. The study population examined was 82,069 
ethnically diverse postmenopausal women who had no 
prior history of chronic diseases (including diabetes or 
cardiovascular disease), of which over 6 years of follow-
up 1675 developed T2DM. Overall, You et al. concluded 
that LTL was found to be weakly associated with diabetes 
risk but was not independent from known epidemiologi-
cal risk factors.
In summary, this review suggests that short LTL has 
been identified in a limited number of population stud-
ies as a risk factor for the development of T2DM. The 
shortening of LTL relates to both OBFC1 genotypes 
and telomerase genotypes such as TERC. Interestingly, 
the interaction between short telomeres and T2DM 
risk appears to involve mitochondrial dysfunction as an 
intermediate process, suggesting a mitochondrial axis 
where underlying gene regulation of telomerase-related 
pathways is important. We suggest that genetic hetero-
geneity within UCPs may directly affect oxidative stress 
that feeds back to influence the fine balance of telomere 
regulation and cell cycle regulation. This in turn may, 
in part, be related to both the development of T2DM 
and enhancing the rate of complications once the dis-
ease is present. The interaction of cardiovascular dis-
ease in association with the development of T2DM is 
important and is likely to associate with some genetic 
components of telomere regulation, but not with all. 
Overall, the accumulated data in this review illustrates 
the emerging influence of genetic factors on LTL and 
T2DM and interplay with mitochondrial function. We 
suggest that there is a likely need to explore the bio-
logical and pathological interactions between UCP, 
telomerase and shelterin regulatory pathways. These 
studies are required to adequately describe the precise 
role of mitochondria on LTL shortening with respect to 
both acute and chronic pathological events. A greater 
understanding of the genetic influences on telomere 
length and T2DM is likely to facilitate risk stratifica-
tion amongst patients, as genomics is progressively 
embraced as a clinical tool in the management of this 
chronic illness.
Authors’ contributions
All authors have made substantial contributions to conception and design 
and drafting of the manuscript; CM conceived the idea for the manuscript, 
and drafted the initial manuscript with ZN, YL reviewed initial drafts for techni-
cal compliance and provided review of references, YZ contributed to the final 
drafts with BH and expanded upon review. BH and CM made the final edits to 
the manuscript. All authors read and approved the final manuscript.
Author details
1 Faculty of Medicine, Rural Clinical School, University of New South Wales, 
Samuels Building, Level 3, Room 327, Sydney 2052, Australia. 2 Discipline 
of Pathology, Bosch Institute, Sydney Medical School, University of Sydney, 
Sydney, Australia. 
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2015   Accepted: 29 February 2016
References
 1. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL (2001) 
Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, 
aging, and heart failure. J Mol Cell Cardiol 33(6):1065–1089. doi:10.1006/
jmcc.2001.1378
 2. Lemasters JJ (2005) Selective mitochondrial autophagy, or mitophagy, as 
a targeted defense against oxidative stress, mitochondrial dysfunction, 
and aging. Rejuvenation Res 8(1):3–5. doi:10.1089/rej.2005.8.3
 3. Blasco MA (2007) Telomere length, stem cells and aging. Nat Chem Biol 
3(10):640–649. doi:10.1038/nchembio.2007.38
 4. Sanders JL, Newman AB (2013) Telomere length in epidemiology: a 
biomarker of aging, age-related disease, both, or neither? Epidemiol Rev 
35:112–131. doi:10.1093/epirev/mxs008
 5. Monickaraj F, Aravind S, Gokulakrishnan K, Sathishkumar C, Prabu P, 
Prabu D et al (2012) Accelerated aging as evidenced by increased 
telomere shortening and mitochondrial DNA depletion in patients 
with type 2 diabetes. Mol Cell Biochem 365(1–2):343–350. doi:10.1007/
s11010-012-1276-0
 6. Price LH, Kao HT, Burgers DE, Carpenter LL, Tyrka AR (2013) Telomeres and 
early-life stress: an overview. Biol Psychiatry 73(1):15–23. doi:10.1016/j.
biopsych.2012.06.025
 7. Guo N, Parry EM, Li LS, Kembou F, Lauder N, Hussain MA et al (2011) 
Short telomeres compromise beta-cell signaling and survival. PLoS One 
6(3):e17858. doi:10.1371/journal.pone.0017858
 8. Armanios M, Alder JK, Parry EM, Karim B, Strong MA, Greider CW (2009) 
Short telomeres are sufficient to cause the degenerative defects 
associated with aging. Am J Hum Genet 85(6):823–832. doi:10.1016/j.
ajhg.2009.10.028
 9. Butt HZ, Atturu G, London NJ, Sayers RD, Bown MJ (2010) Telomere 
length dynamics in vascular disease: a review. Eur J Vasc Endovasc Surg 
40(1):17–26. doi:10.1016/j.ejvs.2010.04.012
 10. Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D 
et al (2003) Telomere shortening in T cells correlates with Alzheimer’s 
disease status. Neurobiol Aging 24(1):77–84
 11. Armanios M (2009) Syndromes of telomere shortening. Annu Rev Genom-
ics Hum Genet 10:45–61. doi:10.1146/annurev-genom-082908-150046
 12. Feldser DM, Hackett JA, Greider CW (2003) Telomere dysfunction and 
the initiation of genome instability. Nat Rev Cancer 3(8):623–627. 
doi:10.1038/nrc1142
 13. Salpea KD, Talmud PJ, Cooper JA, Maubaret CG, Stephens JW, Abelak 
K et al (2010) Association of telomere length with type 2 diabetes, 
oxidative stress and UCP2 gene variation. Atherosclerosis 209(1):42–50. 
doi:10.1016/j.atherosclerosis.2009.09.070
 14. Lowell BB, Shulman GI (2005) Mitochondrial dysfunction and type 2 
diabetes. Science 307(5708):384–387. doi:10.1126/science.1104343
 15. Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of 
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 
51(10):2944–2950
 16. Mulder H (2010) Is shortening of telomeres the missing link between 
aging and the Type 2 Diabetes epidemic? Aging 2(10):634–636
 17. Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A et al 
(2006) Insulin resistance, oxidative stress, hypertension, and leukocyte 
telomere length in men from the Framingham Heart Study. Aging Cell 
5(4):325–330. doi:10.1111/j.1474-9726.2006.00224.x
 18. Olivieri F, Lorenzi M, Antonicelli R, Testa R, Sirolla C, Cardelli M et al 
(2009) Leukocyte telomere shortening in elderly Type2DM patients 
Page 5 of 6Zhou et al. Clin Trans Med  (2016) 5:8 
with previous myocardial infarction. Atherosclerosis 206(2):588–593. 
doi:10.1016/j.atherosclerosis.2009.03.034
 19. Murillo-Ortiz B, Albarran-Tamayo F, Arenas-Aranda D, Benitez-Bribiesca L, 
Malacara-Hernandez JM, Martinez-Garza S et al (2012) Telomere length 
and type 2 diabetes in males, a premature aging syndrome. Aging Male 
15(1):54–58. doi:10.3109/13685538.2011.593658
 20. Fyhrquist F, Saijonmaa O, Strandberg T (2013) The roles of senescence 
and telomere shortening in cardiovascular disease. Nat Rev Cardiol 
10(5):274–283. doi:10.1038/nrcardio.2013.30
 21. Mokini Z, Marcovecchio ML, Chiarelli F (2010) Molecular pathology 
of oxidative stress in diabetic angiopathy: role of mitochondrial and 
cellular pathways. Diabetes Res Clin Pract 87(3):313–321. doi:10.1016/j.
diabres.2009.11.018
 22. Polettini J, Behnia F, Taylor BD, Saade GR, Taylor RN, Menon R (2015) 
Telomere fragment induced amnion cell senescence: a contributor to 
parturition? PLoS ONE 10(9):e0137188. doi:10.1371/journal.pone.0137188
 23. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J (2010) The senescence-related 
mitochondrial/oxidative stress pathway is repressed in human induced 
pluripotent stem cells. Stem Cells 28(4):721–733. doi:10.1002/stem.404
 24. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M et al (2011) Telomere 
dysfunction induces metabolic and mitochondrial compromise. Nature 
470(7334):359–365. doi:10.1038/nature09787
 25. Passos JF, von Zglinicki T (2005) Mitochondria, telomeres and cell senes-
cence. Exp Gerontol 40(6):466–472. doi:10.1016/j.exger.2005.04.006
 26. Cui H, Kong Y, Zhang H (2012) Oxidative stress, mitochon-
drial dysfunction, and aging. J Signal Transduct 2012:646354. 
doi:10.1155/2012/646354
 27. Sahin E, DePinho RA (2012) Axis of ageing: telomeres, p53 and mitochon-
dria. Nat Rev Mol Cell Biol 13(6):397–404. doi:10.1038/nrm3352
 28. Higuchi Y, Maeda T, Guan JZ, Oyama J, Sugano M, Makino N (2009) Diago-
nal earlobe crease are associated with shorter telomere in male Japanese 
patients with metabolic syndrome. Circ J 73(2):274–279
 29. Satoh M, Ishikawa Y, Takahashi Y, Itoh T, Minami Y, Nakamura M (2008) 
Association between oxidative DNA damage and telomere shortening 
in circulating endothelial progenitor cells obtained from metabolic syn-
drome patients with coronary artery disease. Atherosclerosis 198(2):347–
353. doi:10.1016/j.atherosclerosis.2007.09.040
 30. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE et al 
(2006) Cell aging in relation to stress arousal and cardiovascular disease 
risk factors. Psychoneuroendocrinology 31(3):277–287. doi:10.1016/j.
psyneuen.2005.08.011
 31. Hardikar S, Song X, Risques RA, Montine TJ, Duggan C, Blount PL et al 
(2015) Obesity and inflammation markers in relation to leukocyte 
telomere length in a cross-sectional study of persons with Barrett’s 
esophagus. BMC Obes 2:32. doi:10.1186/s40608-015-0063-3
 32. Menke A, Casagrande S, Cowie CC (2015) Leukocyte telomere length and 
diabetes status, duration, and control: the 1999–2002 National Health 
and Nutrition Examination Survey. BMC Endocr Disord 15:52. doi:10.1186/
s12902-015-0050-1
 33. Zee RY, Castonguay AJ, Barton NS, Germer S, Martin M (2010) Mean leu-
kocyte telomere length shortening and type 2 diabetes mellitus: a case-
control study. Transl Res 155(4):166–169. doi:10.1016/j.trsl.2009.09.012
 34. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA (2006) 
Monocyte telomere shortening and oxidative DNA damage in type 2 
diabetes. Diabetes Care 29(2):283–289
 35. Shen Q, Zhao X, Yu L, Zhang Z, Zhou D, Kan M et al (2012) Association 
of leukocyte telomere length with type 2 diabetes in mainland Chinese 
populations. J Clin Endocrinol Metab 97(4):1371–1374. doi:10.1210/
jc.2011-1562
 36. Aviv A, Kark JD, Susser E (2015) Telomeres, atherosclerosis, and human 
longevity: a causal hypothesis. Epidemiology 26(3):295–299. doi:10.1097/
EDE.0000000000000280
 37. Rousset S, Alves-Guerra MC, Mozo J, Miroux B, Cassard-Doulcier AM, 
Bouillaud F et al (2004) The biology of mitochondrial uncoupling pro-
teins. Diabetes 53(Suppl 1):S130–S135
 38. Xiao F, Zheng X, Cui M, Shi G, Chen X, Li R et al (2011) Telomere dysfunc-
tion-related serological markers are associated with type 2 diabetes. 
Diabetes Care 34(10):2273–2278. doi:10.2337/dc10-2431
 39. Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Brand MD (2010) 
Mitochondrial proton and electron leaks. Essays Biochem 47:53–67. 
doi:10.1042/bse0470053
 40. Lentes KU, Tu N, Chen H, Winnikes U, Reinert I, Marmann G et al (1999) 
Genomic organization and mutational analysis of the human UCP2 gene, 
a prime candidate gene for human obesity. J Recept Signal Transduct Res 
19(1–4):229–244. doi:10.3109/10799899909036648
 41. Makino N, Maeda T, Oyama J, Higuchi Y, Mimori K (2009) Improving insu-
lin sensitivity via activation of PPAR-gamma increases telomerase activity 
in the heart of OLETF rats. Am J Physiol Heart Circ Physiol 297(6):H2188–
H2195. doi:10.1152/ajpheart.00421.2009
 42. Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquier D 
et al (1997) Up-regulation of UCP-2 gene expression by PPAR ago-
nists in preadipose and adipose cells. Biochem Biophys Res Commun 
238(2):606–611. doi:10.1006/bbrc.1997.7348
 43. Ito E, Ozawa S, Takahashi K, Tanaka T, Katsuta H, Yamaguchi S et al (2004) 
PPAR-gamma overexpression selectively suppresses insulin secre-
tory capacity in isolated pancreatic islets through induction of UCP-2 
protein. Biochem Biophys Res Commun 324(2):810–814. doi:10.1016/j.
bbrc.2004.08.238
 44. Almsherqi ZA, McLachlan CS, Slocinska MB, Sluse FE, Navet R, Kochergin-
sky N et al (2006) Reduced cardiac output is associated with decreased 
mitochondrial efficiency in the non-ischemic ventricular wall of the 
acute myocardial-infarcted dog. Cell Res 16(3):297–305. doi:10.1038/
sj.cr.7310037
 45. Wang CM, Almsherqi ZA, McLachlan CS, Matthews S, Ramachandran M, 
Tay S et al (2011) Acute starvation in C57BL/6 J mice increases myocardial 
UCP2 and UCP3 protein expression levels and decreases mitochondrial bio-
energetic function. Stress 14(1):66–72. doi:10.3109/10253890.2010.506931
 46. Chen JL, Greider CW (2003) Template boundary definition in mammalian 
telomerase. Genes Dev 17(22):2747–2752. doi:10.1101/gad.1140303
 47. Gallardo F, Laterreur N, Wellinger RJ, Chartrand P (2012) Telomerase 
caught in the act: united we stand, divided we fall. RNA Biol 9(9):1139–
1143. doi:10.4161/rna.21498
 48. Njajou OT, Blackburn EH, Pawlikowska L, Mangino M, Damcott CM, Kwok 
PY et al (2010) A common variant in the telomerase RNA compo-
nent is associated with short telomere length. PLoS One 5(9):e13048. 
doi:10.1371/journal.pone.0013048
 49. Diotti R, Loayza D (2011) Shelterin complex and associated factors at 
human telomeres. Nucleus 2(2):119–135. doi:10.4161/nucl.2.2.15135
 50. Schmidt JC, Dalby AB, Cech TR (2014) Identification of human TERT 
elements necessary for telomerase recruitment to telomeres. Elife. 
doi:10.7554/eLife.03563
 51. Sullivan LB, Santos JH, Chandel NS (2012) Mitochondria and telomeres: 
the promiscuous roles of TIN2. Mol Cell 47(6):823–824. doi:10.1016/j.
molcel.2012.09.006
 52. Martinez P, Gomez-Lopez G, Garcia F, Mercken E, Mitchell S, Flores JM 
et al (2013) RAP1 protects from obesity through its extratelomeric role 
regulating gene expression. Cell Rep 3(6):2059–2074. doi:10.1016/j.
celrep.2013.05.030
 53. Chen LY, Zhang Y, Zhang Q, Li H, Luo Z, Fang H et al (2012) Mitochondrial 
localization of telomeric protein TIN2 links telomere regulation to meta-
bolic control. Mol Cell 47(6):839–850. doi:10.1016/j.molcel.2012.07.002
 54. Zee RY, Ridker PM, Chasman DI (2011) Genetic variants of 11 telomere-
pathway gene loci and the risk of incident type 2 diabetes mellitus: 
the Women’s Genome Health Study. Atherosclerosis 218(1):144–146. 
doi:10.1016/j.atherosclerosis.2011.05.013
 55. Blasco MA (2005) Telomeres and human disease: ageing, cancer and 
beyond. Nat Rev Genet 6(8):611–622. doi:10.1038/nrg1656
 56. Du HY, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM et al (2009) TERC 
and TERT gene mutations in patients with bone marrow failure and the 
significance of telomere length measurements. Blood 113(2):309–316. 
doi:10.1182/blood-2008-07-166421
 57. Goldman F, Bouarich R, Kulkarni S, Freeman S, Du HY, Harrington L et al 
(2005) The effect of TERC haploinsufficiency on the inheritance of tel-
omere length. Proc Natl Acad Sci USA 102(47):17119–17124. doi:10.1073/
pnas.0505318102
 58. Shen Q, Zhang Z, Yu L, Cao L, Zhou D, Kan M et al (2011) Common 
variants near TERC are associated with leukocyte telomere length in the 
Chinese Han population. Eur J Hum Genet 19(6):721–723. doi:10.1038/
ejhg.2011.4
 59. Kedde M, le Sage C, Duursma A, Zlotorynski E, van Leeuwen B, Nijkamp 
W et al (2006) Telomerase-independent regulation of ATR by human 
Page 6 of 6Zhou et al. Clin Trans Med  (2016) 5:8 
telomerase RNA. J Biol Chem 281(52):40503–40514. doi:10.1074/jbc.
M607676200
 60. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR 
et al (2004) Rapid inhibition of cancer cell growth induced by lentivi-
ral delivery and expression of mutant-template telomerase RNA and 
anti-telomerase short-interfering RNA. Cancer Res 64(14):4833–4840. 
doi:10.1158/0008-5472.CAN-04-0953
 61. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, Lee SW et al (2002) Inhibition 
of p21-mediated ROS accumulation can rescue p21-induced senescence. 
EMBO J 21(9):2180–2188. doi:10.1093/emboj/21.9.2180
 62. da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos 
GA Jr, Sakamoto-Hojo ET, Salvadori DM (2010) Cell cycle arrest and 
apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with 
cisplatin and gemcitabine. Exp Biol Med 235(7):814–824. doi:10.1258/
ebm.2010.009322
 63. Luo H, Rankin GO, Li Z, Depriest L, Chen YC (2011) Kaempferol 
induces apoptosis in ovarian cancer cells through activating p53 
in the intrinsic pathway. Food Chem 128(2):513–519. doi:10.1016/j.
foodchem.2011.03.073
 64. Levy D, Neuhausen SL, Hunt SC, Kimura M, Hwang SJ, Chen W et al (2010) 
Genome-wide association identifies OBFC1 as a locus involved in human 
leukocyte telomere biology. Proc Natl Acad Sci USA 107(20):9293–9298. 
doi:10.1073/pnas.0911494107
 65. Saxena R, Bjonnes A, Prescott J, Dib P, Natt P, Lane J et al (2014) Genome-
wide association study identifies variants in casein kinase II (CSNK2A2) 
to be associated with leukocyte telomere length in a Punjabi Sikh 
diabetic cohort. Circ Cardiovasc Genet 7(3):287–295. doi:10.1161/
CIRCGENETICS.113.000412
 66. Wan M, Qin J, Songyang Z, Liu D (2009) OB fold-containing protein 1 
(OBFC1), a human homolog of yeast Stn1, associates with TPP1 and is 
implicated in telomere length regulation. J Biol Chem 284(39):26725–
26731. doi:10.1074/jbc.M109.021105
 67. Lee JH, Cheng R, Honig LS, Feitosa M, Kammerer CM, Kang MS et al (2013) 
Genome wide association and linkage analyses identified three loci-4q25, 
17q23.2, and 10q11.21-associated with variation in leukocyte telomere 
length: the Long Life Family Study. Front Genet 4:310. doi:10.3389/
fgene.2013.00310
 68. Aviv A, Chen W, Gardner JP, Kimura M, Brimacombe M, Cao X et al (2009) 
Leukocyte telomere dynamics: longitudinal findings among young 
adults in the Bogalusa Heart Study. Am J Epidemiol 169(3):323–329. 
doi:10.1093/aje/kwn338
 69. Flynn RL, Zou L (2010) Oligonucleotide/oligosaccharide-binding fold 
proteins: a growing family of genome guardians. Crit Rev Biochem Mol 
Biol 45(4):266–275. doi:10.3109/10409238.2010.488216
 70. Maubaret CG, Salpea KD, Romanoski CE, Folkersen L, Cooper JA, Stepha-
nou C et al (2013) Association of TERC and OBFC1 haplotypes with mean 
leukocyte telomere length and risk for coronary heart disease. PLoS One 
8(12):e83122. doi:10.1371/journal.pone.0083122
 71. You NC, Chen BH, Song Y, Lu X, Chen Y, Manson JE et al (2012) A prospec-
tive study of leukocyte telomere length and risk of type 2 diabetes in 
postmenopausal women. Diabetes 61(11):2998–3004. doi:10.2337/
db12-0241
